Comparative Pharmacology
Head-to-head clinical analysis: FACTIVE versus QUIXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FACTIVE versus QUIXIN.
FACTIVE vs QUIXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gemifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
Quixin (levofloxacin) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
400 mg orally once daily for 5 days for acute exacerbation of chronic bronchitis; 400 mg orally once daily for 7 days for community-acquired pneumonia; 400 mg orally once daily for 5 days for acute bacterial sinusitis.
One to two drops in affected eye(s) every 2 hours while awake, up to 8 times daily for 7-14 days.
None Documented
None Documented
12.5 hours (range 10-16 hours), supporting once-daily dosing.
Terminal elimination half-life: 6–8 hours in adults with normal renal function; prolonged in renal impairment (up to 20 hours if CrCl <30 mL/min).
Renal excretion of unchanged drug accounts for approximately 61% of the administered dose; fecal elimination accounts for about 35%, with a minor biliary component.
Renal (approximately 70% unchanged in urine); biliary/fecal (~30%, partly as metabolites and unchanged drug).
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic